NASDAQ$EVLO

Evelo Biosciences Inc · Q3 2019 earnings

Q3 2019 earnings · · Investor relations

Headline financials

Total Revenue

$100K

Previous: $0.00
EPS (adj)

-$13.40

Previous: -$10.00-34.0%
Capital Expenditures

-$2.57M

Previous: -$4.23M+39.2%
Free Cash Flow

-$55.6M

Previous: -$36.1M-54.1%
Net Income

-$21.6M

Previous: -$15.9M-36.4%
Operating Income

-$21.5M

Previous: -$16.5M-30.6%
Gross Profit

$100K

Previous: $0.00
Cash & Equivalents

$97.1M

Previous: $79.7M+21.8%
Total Assets

$111M

Previous: $176M-36.7%
R&D Expense

$15.6M

Previous: $11.2M+39.0%

Revenue & EPS history

Evelo · Revenue · Quarterly

$100K

Q3 2019

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2019

Historical avgQ3 2019

+1.3%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-9.7%

Avg return

30 days after

54%

13 / 24 earnings

Positive

+32.3%

Q2 2023

Best reaction

-20.3%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2023+0.0%+0.0%-9.8%
Q3 2023-7.6%+4.5%+3.8%
Q2 2023+32.3%-30.5%-41.0%
Q1 2023+2.9%+10.2%-28.8%
Q4 2022-17.8%-27.0%-46.9%
Q3 2022+3.3%-3.3%-8.5%
Q2 2022-7.1%-10.5%-25.4%
Q1 2022-20.3%-14.5%-2.4%
Q4 2021+29.4%+13.5%-26.3%
Q3 2021+10.2%+27.0%+6.0%
Q2 2021-0.9%+5.0%+20.7%
Q1 2021+8.8%-14.4%+11.0%
Q4 2020+14.5%+21.2%+1.6%
Q3 2020-12.9%-5.9%+14.0%
Q2 2020-1.6%-0.5%+15.2%
Q1 2020-5.7%-14.0%-20.9%
Q4 2019+1.8%+12.2%-28.4%
Q3 2019-3.3%-6.1%-35.9%
Q2 2019+3.9%-2.2%+7.0%
Q1 2019+0.8%-1.5%-11.8%
Q4 2018+1.3%+3.0%-6.9%
Q3 2018+0.2%+3.4%+3.7%
Q2 2018-3.4%-5.9%+2.6%
Q1 2018+1.8%+2.2%-24.8%
Q4 2017
Q3 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro